C1 sequence for expression of said polypeptide, and (b) expressing said nucleic acid in said cell, wherein expressing said nucleic acid in said cell induces apoptosis of said cell.

85. (Amended) The method of claim 81, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

86. (Amended) The method of claim 81, wherein said nucleic acid is in an C2 adenoviral vector or a retroviral vector.

87. (Amended) The method of claim 81, wherein said cell is a cancer cell.

Sub B1 88. (Twice Amended) A pharmaceutical composition comprising (i) an expression vector comprising a nucleic acid encoding a polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, and (ii) a pharmaceutically acceptable carrier, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said polypeptide in a mammalian cell.

92. (Amended) The composition of claim 88, wherein said regulatory sequence C3 is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

C 3

93. (Amended) The composition of claim 88, wherein said nucleic acid is in an adenoviral vector or a retroviral vector.

Sub B2

C 4

95. (Twice Amended) An expression vector comprising a nucleic acid encoding a polypeptide comprising the sequence of SEQ ID NO.: 4 and capable of inducing apoptosis, wherein said nucleic acid is operably linked to a heterologous regulatory sequence for expression of said polypeptide in a mammalian cell.

99. (Amended) The expression vector of claim 95, wherein said regulatory sequence is capable of expressing said nucleic acid in a constitutive, inducible, or cell-type specific manner.

C 5

100. (Amended) The expression vector of claim 95, wherein said expression vector is an adenoviral vector or a retroviral vector.